Safety and Immunogenicity of Novartis Meningococcal B Vaccine Formulated With OMV Manufactured at Two Different Sites, in Healthy Adolescents Aged 11-17 Years
PHASE3
The primary objective of this study is to demonstrate the equivalence of rM...
Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine Administered to Healthy Adolescents According to Different Vaccination Schedules
PHASE2
The proposed study is aimed to assess the antibody response and short-term ...
One Year Antibody Persistence After a Fourth Dose Boost or Two Catch-Up Doses of Novartis Meningococcal B Recombinant Vaccine Administered Starting From 12 Months of Age and Response to a Third Dose Boost or Two Catch-Up Doses Starting at 24 Months of Age
PHASE3
One year antibody persistence after the fourth dose boost or two catch-up d...
Status
Completed
Location
amostatná ordinace praktického lékaře pro děti a dorost Jindřichův Hradec